Pfizer Lines Up Trio Of US Biosimilar Launches

Bevacizumab, Rituximab And Trastuzumab Slated For US Entry

 
• By Aidan Fry

By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.

Toy_Cars
Pfizer expects within the next few months to bring three biosimilars to the US market • Source: Shutterstock

More from Biosimilars

More from Products